Date: Nov. 2 <sup>th</sup> , 2021 Your Name:Jin Li	
Manuscript Title: Identifying <sup>18</sup> F-FDG PET-metabolize Radiomic Signature for Lung Adenocarcino	ma
Prognosis by Leveraging Prognostic Transcriptomic Module	
Manuscript number (if known): QIMS-21-706	_
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that	ar

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Yo Ma Pr	te: Nov. 2 <sup>th</sup> , 2021 ur Name:Yixin Liu_ nuscript Title: Identif ognosis by Leveraging Prog nuscript number (if known)	gnostic Transcriptomic Mo		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current	
to	• •	ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.	
	item #1 below, report all sup e time frame for disclosure is	•	d in this manuscript without time limit. For all other item	15,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

No time limit for this item.

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Da	te: Nov. 2 <sup>th</sup> , 2021							
Yo	ur Name:Wenlei Dong	_						
Ma	Manuscript Title: Identifying <sup>18</sup> F-FDG PET-metabolize Radiomic Signature for Lung Adenocarcinoma							
	Prognosis by Leveraging Prognostic Transcriptomic Module							
Ma	anuscript number (if known)	): QIMS-2	21-706					
rel pa to rel The ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only.  e author's relationships/act	manuscript. "Related" mede affected by the content of the author's relationship ivities/interests should be the content of the	ips/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive					
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other items					
		Name all entities with	Specifications/Comments					
		whom you have this	(e.g., if payments were made to you or to your					
		relationship or indicate	institution)					
		none (add rows as						
		needed)	I planning of the week					
		Time frame: Since the initia	I planning or the work					
L	All support for the present	XNone						
	manuscript (e.g., funding, provision of study materials,							
	medical writing, article							
	processing charges, etc.)							
	No time limit for this item.							

ı			Time frame: past	36 months
	2	Grants or contracts from	XNone	
		any entity (if not indicated		
		in item #1 above).		
	3	Royalties or licenses	XNone	
	4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

You Ma Pro	Date: Nov. 2 <sup>th</sup> , 2021 Your Name:Yang Zhou Manuscript Title: Identifying <sup>18</sup> F-FDG PET-metabolize Radiomic Signature for Lung Adenocarcinoma Prognosis by Leveraging Prognostic Transcriptomic Module Manuscript number (if known): QIMS-21-706				
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.					
	e following questions apply nuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>		
to i	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone			

Time frame: past 36 months

X\_\_None

X\_\_None

X\_\_None

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

3

4

any entity (if not indicated

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

	te: Nov. 2 <sup>th</sup> , 2021		
	ur Name:Jingquan Wu		
		• 0	bolize Radiomic Signature for Lung Adenocarcinoma
	ognosis by Leveraging Prog		
Ma	nuscript number (if known)	): QIMS-	21-706
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current
to me	the epidemiology of hypertodication, even if that medic	ension, you should declare cation is not mentioned in	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
	e time frame for disclosure i		,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,	XNone	
provision of study materials,			
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		<u> </u>	<del>-  </del>

2

3

4

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

X\_\_None

\_None

X\_\_None

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Da	te: Nov. 2 <sup>th</sup> , 2021			
Yo	ur Name:Kuan Luan			
Ma	nuscript Title: Identi	fying <sup>18</sup> F-FDG PET-meta	bolize Radiomic Signature for Lung Adenocarcinoma	
Pr	ognosis by Leveraging Pro	gnostic Transcriptomic M	Iodule	
Ma	nuscript number (if known	): QIMS-	-21-706	
rela par to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the current	
to me	the epidemiology of hypert edication, even if that medic	ension, you should declare cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertai e all relationships with manufacturers of antihypertensiv the manuscript. ed in this manuscript without time limit. For all other ite	e
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		needed)		
		Time frame: Since the initial	al planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone		
	No time limit for this item.			
		Time frame: pas	t 36 months	
<u>)</u>	Grants or contracts from any entity (if not indicated	XNone		

in item #1 above).

Royalties or licenses

Consulting fees

X\_\_None

X\_\_None

3

4

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

Yo Ma Pr	te: Nov. 2 <sup>th</sup> , 2021 ur Name:Lishuang Qi anuscript Title: Identif ognosis by Leveraging Prog anuscript number (if known)	gnostic Transcriptomic M		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the sound of the manuscript. If you are in doubt about whether to list a so.	
	e following questions apply inuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperto edication, even if that medic item #1 below, report all su	ension, you should declare ation is not mentioned in t pport for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other item	
the	e time frame for disclosure i	s the past 36 months.		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
l	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone		

			Time frame: past	36 months
ſ	2	Grants or contracts from	XNone	
		any entity (if not indicated		
		in item #1 above).		
	3	Royalties or licenses	XNone	
	4	Consulting fees	XNone	
=		·		

No time limit for this item.

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	<b>.</b>		
8	Patents planned, issued or	X None	
	pending		
	. 0		
	5		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement: